Hereditary Angioedema Market Opportunities And Regional Outlook 2023
The global hereditary angioedema market size was valued at USD 2,737.3 million in 2022 and is poised to grow at a significant CAGR of 37.4% during the forecast period 2023-29. It also includes market size and projection estimations for each of the five major regions from 2023 to 2029. The research report includes historical data, trending features, and market growth estimates for the future. Furthermore, the study includes a global and regional estimation and is further split by nations and categories within each region. The research also includes factors and barriers to the hereditary angioedema market growth, as well as their impact on the market's future growth. The report gives a comprehensive overview of both primary and secondary data.
The global hereditary angioedema market segmentation:
1) By Product: Kalbitor, Ruconest, Icatibant, Firazyre, Berinert, Orladeyo, Cinryze, Haegarda and Takhzyro
2) By Drug Class: C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor and Others
3) By Route of Administration: Intravenous, Subcutaneous and Oral
The primary factors of the hereditary angioedema market drivers are the increasing r&d and funding for orphan drug development. The hereditary angioedema market report helps to provide the best results for business enhancement and business growth. It further helps to obtain the reactions of consumers to a novel product or service. It becomes possible for business players to take action for changing perceptions. It uncovers and identifies potential issues of the customers. It becomes easy to obtain the reactions of the customers to a novel product or service. It also enlightens further advancement, so it suits its intended market.
The hereditary angioedema market research report gives a comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America was the largest region in the hereditary angioedema market report, accounting for the highest share in 2022. It was followed by Asia Pacific, and then the other regions.
Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=482979
The important profiles and strategies adopted by the hereditary angioedema market key players are CSL Behring (Garadacimab), Takeda, Pharming, Biocryst Pharmaceutics (BCX-4161), Pharvaris (PHA 121), Ionis Pharmaceuticals (Donidalorsen), Attune Pharmaceuticals (ATN-249), Arrowhead Pharmaceuticals (ARO-F12) is covered here to help them in strengthening their place in the market.
English
Arabic
Français
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian